Sessão de Encontro com o Autor – Tema Livre (Pôster)


Código

P77

Área Técnica

Órbita

Instituição onde foi realizado o trabalho

  • Principal: HCFMUSP

Autores

  • CRISTIANE DE ALMEIDA LEITE (Interesse Comercial: NÃO)
  • THAIS DE SOUSA PEREIRA (Interesse Comercial: NÃO)
  • JEANE CHIANG (Interesse Comercial: NÃO)
  • RODRIGO BERNAL MORITZ (Interesse Comercial: NÃO)
  • ALLAN CHRISTIAN PIERONI GONCALVES (Interesse Comercial: NÃO)
  • MARIO LUIZ RIBEIRO MONTEIRO (Interesse Comercial: NÃO)

Título

QUALITY OF LIFE IN PATIENTS WITH GRAVES’ ORBITOPATHY SUBMITTED TO ORBITAL DECOMPRESSION: COMPARISON BETWEEN INFERIOR-MEDIAL AND BALANCED TECHNIQUES

Objetivo

To evaluate the surgical results of inferior-medial wall orbital decompression (IM-OD) and balanced medial plus lateral wall orbital decompression (ML-OD) in patients with Graves’ orbitopathy (GO) in the inactive phase regarding exophthalmos reduction and to compare the effects on quality of life of both surgical techniques.

Método

Forty-two patients with inactive GO were randomly divided into two groups and submitted to one of two orbital decompression (OD) techniques: IM-OD or ML-OD. Pre- and postoperative assessments included Hertel's exophthalmometry and a validated quality of life questionnaire (GO-QoL). The results of the two groups were compared.

Resultado

Exophthalmos reduction was statistically significant in both groups (p<0.001), but greater in patients undergoing ML-OD (p=0.010). Both OD techniques did not increase the visual functioning subscale score on the GO-QoL (IM-OD p=0.362; ML-OD p=0.727), but, on the other hand, there was a statistically significant improvement in the appearance subscale score in patients undergoing ML-OD (p=0.006).

Conclusão

IM-OD is a good alternative for patients not requiring large exophthalmos reduction. ML-OD offers more significant exophthalmos reduction; in addition, scores better on the GO-QoL regarding appearance improvement, becoming a good option for the esthetic-functional rehabilitation of GO patients. Clinical trial registration: ClinicalTrials.gov ID: NCT03278964. Unique Protocol ID: 39748114.0.0000.0068

Promotor

Realização - CBO

Organização

Organizadora

Transporte Terrestre

Transporte Terrestre

Agência de Turismo

Agência Oficial de Turismo

Agência Web

Sistema de Gerenciamento desenvolvido por Inteligência Web

Patrocinador Platina

Genom
Johnson & Johnson

Patrocinador Ouro

Allergan

Patrocinador Prata

Alcon
Latinofarma

Patrocinador Bronze

Essilor
Ofta
Zeiss

Patrocínio

Roche

66º Congresso Brasileiro de Oftalmologia

07 a 10 de setembro de 2022 | Curitiba/PR

Política de privacidade